Natera (NASDAQ:NTRA) Insider Solomon Moshkevich Sells 15,160 Shares

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 15,160 shares of the business’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $326.89, for a total value of $4,955,652.40. Following the sale, the insider directly owned 110,859 shares of the company’s stock, valued at $36,238,698.51. This represents a 12.03% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Solomon Moshkevich also recently made the following trade(s):

• On Tuesday, September 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $320.73, for a total transaction of $962,190.00.
• On Monday, August 3rd, Solomon Moshkevich sold 3,410 shares of Natera stock. The stock was sold at an average price of $265.58, for a total transaction of $905,627.80.
• On Tuesday, July 28th, Solomon Moshkevich sold 1,204 shares of Natera stock. The stock was sold at an average price of $254.07, for a total transaction of $305,900.28.
• On Monday, July 27th, Solomon Moshkevich sold 1,010 shares of Natera stock. The shares were sold at an average price of $260.49, for a total transaction of $263,094.90.
• On Wednesday, July 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $272.90, for a total transaction of $818,700.00.

Natera Stock Up 0.8%

NTRA stock opened at $327.67 on Friday. Natera, Inc. has a twelve month low of $157.43 and a twelve month high of $343.18. The company has a market cap of $47.23 billion, a P/E ratio of -240.93 and a beta of 1.54. The business’s fifty day moving average is $291.29 and its 200-day moving average is $237.00.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.02. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%.The business had revenue of $752.75 million during the quarter, compared to analysts’ expectations of $661.24 million. During the same period in the previous year, the firm earned ($0.74) earnings per share. The firm’s quarterly revenue was up 37.7% compared to the same quarter last year. Research analysts anticipate that Natera, Inc. will post -1.02 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Natera

A number of hedge funds have recently modified their holdings of the business. Trust Co. of Vermont bought a new stake in Natera during the 2nd quarter worth approximately $26,000. Elevation Wealth Partners LLC acquired a new stake in Natera during the 2nd quarter worth approximately $30,000. Continuum Advisory LLC bought a new position in Natera in the second quarter valued at approximately $33,000. Reflection Asset Management acquired a new position in shares of Natera in the fourth quarter valued at approximately $29,000. Finally, Rakuten Securities Inc. acquired a new position in shares of Natera in the second quarter valued at approximately $35,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Analyst Ratings Changes

NTRA has been the subject of a number of recent analyst reports. Zacks Research raised Natera from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 12th. Sanford C. Bernstein started coverage on shares of Natera in a research note on Friday, June 26th. They set an “outperform” rating and a $310.00 price objective on the stock. JPMorgan Chase & Co. boosted their price objective on shares of Natera from $315.00 to $360.00 and gave the company an “overweight” rating in a report on Friday, August 7th. UBS Group set a $260.00 target price on shares of Natera in a research note on Wednesday, June 24th. Finally, The Goldman Sachs Group initiated coverage on shares of Natera in a report on Friday, June 5th. They issued a “neutral” rating and a $245.00 target price on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $319.38.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.